Organisation: Sanofi

The patentees join Amgen as the only pharma companies yet to use the pan-European court

24 April 2024

IAM speaks to both sides following landmark document access hearing

12 March 2024

The company will be looking to make up for the terrible reversal of fortunes it has suffered in long-running spat with Sanofi and Regeneron

29 February 2024

Newly released report throws light on which life sciences companies have the most dynamic IP portfolios

22 February 2024

IAM talked with Petro Terblanche, CEO of Afrigen Biologics, about the WHO vaccine hub and its IP strategy

21 February 2024

Litigation from Australia, India, Colombia and Europe illustrates the pivotal role played by the courts, especially in the most volatile areas of patent law

19 February 2024

Division-centric approach may provide opportunities for creative litigants but perils for unwary ones

09 February 2024

Featured in The Patent Litigation Review 2024

International patent protection is now part-and-parcel for any significant drug or therapeutic, and, as a result, disputes over patent ownership and infringement now regularly implicate a myriad of related laws across international venues. In recent years, there has been a trend towards more complex and high-stakes global patent disputes in the pharmaceutical industry, including parallel litigation across multiple jurisdictions. 

29 January 2024

The dawn of a new era for CRISPR patent strategy, multiplying mRNA patent wars, and 10x Genomics and NanoString’s cross-border spat were among the developments that defined the last 12 months

02 January 2024

The Amgen patent enablement ruling was 2023’s crowning gem but the US Supreme Court also issued major trademark decisions and has a host of patent appeals pending

29 December 2023